行情

CASI

CASI

CASI制药
NASDAQ

实时行情|Nasdaq Last Sale

2.970
-0.060
-1.98%
交易中 12:00 01/27 EST
开盘
3.010
昨收
3.030
最高
3.010
最低
2.950
成交量
2.77万
成交额
--
52周最高
3.830
52周最低
2.830
市值
2.37亿
市盈率(TTM)
-6.6907
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CASI 新闻

  • What You Must Know About CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Beta Value
  • Simply Wall St..1天前
  • Have Insiders Been Buying CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Shares?
  • Simply Wall St..2019/12/20 10:27
  • Week In Review: Alphamab Oncology Plans $350 Million Hong Kong IPO
  • Seeking Alpha - Article.2019/12/08 19:06
  • CASI Pharma's CD19 CAR-T clinical trial applications OK'd in China
  • Seeking Alpha - Article.2019/12/04 11:49

更多

所属板块

生物技术和医学研究
-1.03%
制药与医学研究
-0.45%

热门股票

名称
价格
涨跌幅

CASI 简况

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).
展开

Webull提供CASI Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。